Probiotics for everyone! The novel immunobiotic lactobacillus rhamnosus CRL1505 and the beginning of social probiotic programs in Argentina
Probiotics for everyone! The novel immunobiotic lactobacillus rhamnosus CRL1505 and the beginning of social probiotic programs in Argentina
复制标题
适合所有人的益生菌！
DOI：
--
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
S. Alvarez
中科院分区：
文献类型：
--
作者：
J. Villena;S. Salva;M. Núñez;J. Corzo;René Tolaba;Julio Faedda;G. Font;S. Alvarez
鼠李糖乳杆菌CRL1505 （Lr1505）刺激肠道和呼吸道的免疫反应，提高免疫功能正常和免疫功能低下小鼠对鼠伤寒沙门菌和肺炎链球菌感染的抵抗力。考虑到呼吸道传染病仍然是发展中国家学龄前儿童死亡的一个主要原因，本研究的目的是评估Lr1505对儿童健康的影响。对298名参加日托中心的健康儿童（2-5岁）进行随机对照双盲临床试验。将含有Lr1505的酸奶给予儿童6个月（每周5次）。结果与来自同一社区的儿童接受安慰剂酸奶（不含益生菌）的结果进行了统计比较。幼儿服用Lr1505降低了感染的发生率：安慰剂组66%的儿童出现感染症状，而Lr1505组只有34%的病例被检测到。安慰剂组与Lr1505组在肠道感染、上呼吸道感染、心绞痛发生率方面比较，差异均有统计学意义（P <0.05）。与服用安慰剂的儿童相比，服用Lr1505的儿童发烧次数更少，需要的抗生素也更少。Lr1505的保护作用与黏膜IgA抗体水平升高有关。Lr1505是一种很有前途的资源，可用于制定预防黏膜感染的策略，可能是医学应用的有效工具。这种新的益生菌菌株已被纳入阿根廷官方营养计划，并给20多万儿童服用。由于省政府对含有鼠李糖乳杆菌CRL1505的益生菌酸奶的不断需求，该项目鼓励了当地的牛奶生产，同时将创新纳入中小企业。
Lactobacillus rhamnosus CRL1505 (Lr1505) stimulates immune responses in the gut and in the respiratory tract and improves resistance against Salmonella typhimurium and Streptococcus pneumoniae infections in immunocompetent and immunocompromised mice. Considering that respiratory infectious diseases continue to be a major cause of death among preschool children in developing countries, the aim of the present study was to evaluate the effect of Lr1505 on the health of children. A randomized-controlled double-blind clinical trial in 298 healthy children (2-5 years old), attending daycare centers was performed. Yogurt containing Lr1505 was administered to children for 6 months (five times a week). Results were statistically compared with those of children from the same community that received a placebo yogurt (without probiotic). Administration of Lr1505 to young children reduced the incidence of infections: 66% of children in the placebo group presented symptoms of infection while only 34% of cases were detected in the Lr1505 group. Significant differences ( P <0.05) were detected in the incidence of intestinal infections, upper respiratory tract infections and angina when placebo and Lr1505 groups were compared. Children fed Lr1505 experienced fewer fevers and needed fewer antibiotics than those receiving the placebo. The protective effect of Lr1505 was associated with increased levels of mucosal IgA antibodies. Lr1505 is a promising resource for the development of prevention strategies against mucosal infections that could be effective tools for medical application. This new probiotic strain has been included into official Nutritional Programs in Argentina and it is given to more than 200 thousand children. This project has encouraged local milk production, thanks to the constant demand of probiotic yogurt containing L. rhamnosus CRL1505 by provincial governments, while incorporating innovation to small and medium enterprises.